Esserman Archives - Agendia

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
Gallery
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Endocrine, Evidence, MammaPrint, STO-3

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More

kevin2024-06-28T12:13:13-04:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers
Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

Evidence, MammaPrint, Other

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub Read More

kevin2024-03-25T10:55:45-04:00December 2nd, 2011|Evidence, MammaPrint, Other|

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients
Newsroom

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.